Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.71 |
| ▸ | FAAH | O00519 | 5/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195404 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL9432343 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL7557934 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL4683998 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL7555060 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL97364 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL7554107 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL7556481 | 1.00 | CASP2 (0.71) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL9202025 | 0.94 | CASP2 (0.68) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL4681345 | 0.94 | CASP2 (0.68) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1221440-B1 | Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators | OTSUKA PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0514667-B1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5244898-A | Vasopressin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | CASP2 1689/4885FAAH 4020/4885NAAA 4652/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | CASP2 2690/4885FAAH 3506/4885NAAA 4824/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | CASP2 2690/4885FAAH 3506/4885NAAA 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.